These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 38570449)

  • 1. The Abundance of KRAS and RAS Gene Mutations in Cancer.
    Stites EC
    Methods Mol Biol; 2024; 2797():13-22. PubMed ID: 38570449
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The mutational spectrum of HRAS, KRAS, NRAS and FGFR3 genes in bladder cancer.
    Ouerhani S; Elgaaied AB
    Cancer Biomark; 2011-2012; 10(6):259-66. PubMed ID: 22820081
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers.
    Janku F; Lee JJ; Tsimberidou AM; Hong DS; Naing A; Falchook GS; Fu S; Luthra R; Garrido-Laguna I; Kurzrock R
    PLoS One; 2011; 6(7):e22769. PubMed ID: 21829508
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ras protein abundance correlates with Ras isoform mutation patterns in cancer.
    Hood FE; Sahraoui YM; Jenkins RE; Prior IA
    Oncogene; 2023 Apr; 42(15):1224-1232. PubMed ID: 36864243
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interactions between wild-type and mutant Ras genes in lung and skin carcinogenesis.
    To MD; Rosario RD; Westcott PM; Banta KL; Balmain A
    Oncogene; 2013 Aug; 32(34):4028-33. PubMed ID: 22945650
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PIK3CA, HRAS and KRAS gene mutations in human penile cancer.
    Andersson P; Kolaric A; Windahl T; Kirrander P; Söderkvist P; Karlsson MG
    J Urol; 2008 May; 179(5):2030-4. PubMed ID: 18355852
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Kirsten Ras* oncogene: significance of its discovery in human cancer research.
    Tsuchida N; Murugan AK; Grieco M
    Oncotarget; 2016 Jul; 7(29):46717-46733. PubMed ID: 27102293
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A requirement for wild-type Ras isoforms in mutant KRas-driven signalling and transformation.
    Bentley C; Jurinka SS; Kljavin NM; Vartanian S; Ramani SR; Gonzalez LC; Yu K; Modrusan Z; Du P; Bourgon R; Neve RM; Stokoe D
    Biochem J; 2013 Jun; 452(2):313-20. PubMed ID: 23496764
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nras and Kras mutation in Japanese lung cancer patients: Genotyping analysis using LightCycler.
    Sasaki H; Okuda K; Kawano O; Endo K; Yukiue H; Yokoyama T; Yano M; Fujii Y
    Oncol Rep; 2007 Sep; 18(3):623-8. PubMed ID: 17671710
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comprehensive survey of HRAS, KRAS, and NRAS mutations in proliferative thyroid lesions from an ethnically diverse population.
    Schulten HJ; Salama S; Al-Ahmadi A; Al-Mansouri Z; Mirza Z; Al-Ghamdi K; Al-Hamour OA; Huwait E; Gari M; Al-Qahtani MH; Al-Maghrabi J
    Anticancer Res; 2013 Nov; 33(11):4779-84. PubMed ID: 24222113
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinicopathologic characteristics and gene expression analyses of non-KRAS 12/13, RAS-mutated metastatic colorectal cancer.
    Morris VK; Lucas FAS; Overman MJ; Eng C; Morelli MP; Jiang ZQ; Luthra R; Meric-Bernstam F; Maru D; Scheet P; Kopetz S; Vilar E
    Ann Oncol; 2014 Oct; 25(10):2008-2014. PubMed ID: 25009008
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Extended-spectrum of
    Basdemirci M; Zamani A; Zamani AG; Findik S; Yildirim MS
    Indian J Cancer; 2022; 59(2):236-243. PubMed ID: 34380837
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular epidemiology and diagnostics of KRAS mutations in human cancer.
    Timar J; Kashofer K
    Cancer Metastasis Rev; 2020 Dec; 39(4):1029-1038. PubMed ID: 32725342
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Are all RAS mutations the same? Coexisting KRAS and NRAS mutations in a caecal adenocarcinoma and contiguous tubulovillous adenoma.
    Vagaja NN; Parry J; McCallum D; Thomas MA; Bentel JM
    J Clin Pathol; 2015 Aug; 68(8):657-60. PubMed ID: 25926041
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Classification of KRAS-Activating Mutations and the Implications for Therapeutic Intervention.
    Johnson C; Burkhart DL; Haigis KM
    Cancer Discov; 2022 Apr; 12(4):913-923. PubMed ID: 35373279
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Explaining the preponderance of Kras mutations in human cancer: An isoform-specific function in stem cell expansion.
    Quinlan MP; Settleman J
    Cell Cycle; 2008 May; 7(10):1332-5. PubMed ID: 18418066
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Origin and Evolution of RAS Membrane Targeting.
    García-España A; Philips MR
    Oncogene; 2023 May; 42(21):1741-1750. PubMed ID: 37031342
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multiplexed screens identify RAS paralogues HRAS and NRAS as suppressors of KRAS-driven lung cancer growth.
    Tang R; Shuldiner EG; Kelly M; Murray CW; Hebert JD; Andrejka L; Tsai MK; Hughes NW; Parker MI; Cai H; Li YC; Wahl GM; Dunbrack RL; Jackson PK; Petrov DA; Winslow MM
    Nat Cell Biol; 2023 Jan; 25(1):159-169. PubMed ID: 36635501
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Significance of Somatic Mutations in RAS/RAF/MAPK Signaling Pathway in Moroccan and North African Colorectal Cancer Patients.
    Benmokhtar S; Laraqui A; El Boukhrissi F; Hilali F; Bajjou T; Jafari M; El Zaitouni S; Baba W; El Mchichi B; Elannaz H; Lahlou IA; Chahdi H; Oukabli M; Mahfoud T; Tanz R; Ichou M; Ennibi K; Dakka N; Sekhsokh Y
    Asian Pac J Cancer Prev; 2022 Nov; 23(11):3725-3733. PubMed ID: 36444585
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The extended spectrum of RAS-MAPK pathway mutations in colorectal cancer.
    Costigan DC; Dong F
    Genes Chromosomes Cancer; 2020 Mar; 59(3):152-159. PubMed ID: 31589789
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.